Indian Army Department Of Military Affairs Tender CENTRAL DELHI Tab Daralutamide 300mg, Inj Ustekinumab 90mg 2026

Tender Overview

The tender is issued by the Indian Army under the Department Of Military Affairs for the purchase of Tab Daralutamide 300mg and Inj Ustekinumab 90mg in the Central Delhi, Delhi 110002 area. The estimated value and item quantities are not disclosed, while the EMD is stated as ₹24,173. The tender references a flexible quantity approach via an option clause allowing +/- up to 25% variation, with extended delivery timelines linked to the original delivery period. This procurement appears to target pharmaceutical products for military healthcare needs, with delivery terms tied to bid quantity adjustments and contract execution periods. The absence of BOQ items underscores potential variability in scope or awaiting further specification from the buyer. The opportunity is positioned for pharmaceutical suppliers capable of supporting large-scale public sector medical requirements with compliant delivery schedules.

Technical Specifications & Requirements

• Product categories: Tab Daralutamide 300mg (oral medication) and Inj Ustekinumab 90mg (injectable biologic).
• EMD: ₹24,173 (money deposit for bid security).
• Quantity flexibility: up to 25% increase/decrease during contract and currency of contract; proposed delivery time scales depend on original delivery period with minimum 30 days, calculated as (increased quantity ÷ original quantity) × original delivery period.
• Delivery terms: delivery period adjustments when option clause exercised; extended delivery permissible within contracted rates.
• No BOQ items available; scope likely to be clarified in subsequent communications or ATC documents.
• Notes: No specified start/end dates or location changes beyond Central Delhi; bidders should prepare to meet military procurement pharma standards and ATC terms.

Terms, Conditions & Eligibility

• Option Clause: Purchaser may modify quantity by up to 25% at contract placement and during currency.
• Delivery timeline: Calculated extension formula with a minimum of 30 days; extended periods remain within contracted rates.
• Bid compliance: Bidders must adhere to the ATC/Buyer Added Terms; quantity adjustments may affect delivery planning and pricing.
• EMD requirement: ₹24,173 as bid security; ensure readiness to submit along with technical bid.
• No BOQ items: Indicates contingent scope; bid readiness to accommodate potential scope change.
• Standards: Not specified in data; bidders should align with standard pharmaceutical procurement practices for military use and ATC terms.